FCGR2A and breast carcinoma: When given in combination with mAb directed against tumor-associated antigens (TAA) CD16-CR and CD32-CR T cells can eliminate breast cancer cells, including the TNBC cells in vitro by antibody-dependent cellular cytotoxicity (ADCC) [183–185].